Patents by Inventor Curtis Lockshin
Curtis Lockshin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240269300Abstract: Novel proteins and compounds conjugated with polysialic acid (PSA) are provided herein. Also provided are methods of using these compounds and methods of treatment of various diseases and disorders. The novel compounds provided herein have improved pharmacodynamic and/or pharmacokinetic properties, improved effectiveness, and other desirable properties.Type: ApplicationFiled: March 12, 2024Publication date: August 15, 2024Applicant: XENETIC BIOSCIENCES, INC.Inventor: Curtis LOCKSHIN
-
Publication number: 20220105190Abstract: Novel proteins and compounds conjugated with polysialic acid (PSA) are provided herein. Also provided are methods of using these compounds and methods of treatment of various diseases and disorders. The novel compounds provided herein have improved pharmacodynamic and/or pharmacokinetic properties, improved effectiveness, and other desirable properties.Type: ApplicationFiled: February 4, 2020Publication date: April 7, 2022Applicant: Lipoxen Technologies LimitedInventor: Curtis LOCKSHIN
-
Publication number: 20220023430Abstract: A composition comprising a population of polysaccharide-blinatumomab conjugates, wherein the polysaccharide is covalently linked to the blinatumomab. A method of increasing the efficacy of a therapeutic agent in the treatment of B-cell precursor acute lymphoblastic leukemia (ALL), wherein the therapeutic agent is a PSA-drug conjugate, wherein the conjugate comprises PSA covalently linked to blinatumomab, and wherein the PSA of the conjugate binds to DNA and histones of NET extracellular fibrils.Type: ApplicationFiled: November 13, 2019Publication date: January 27, 2022Applicant: Lipoxen Technologies LimitedInventors: Anton Igonin, Dmitry Genkin, Curtis Lockshin
-
Patent number: 7671087Abstract: One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to asthma, neuropathic pain, persistent pain, inflammatory pain, hyperactivity, hypertension, brain ischemia, Parkinson's disease, spasticity, Tourette's syndrome, schizophrenia, hemorrhagic shock, septic shock, cardiac shock, migrane, Horton's headache, multiple sclerosis, anorexia, AIDS wasting syndrome, organ rejection, autoimmune diseases, allergy, arthritis, Crohn's disease, malignant gliomas, neurodegenerative diseases, Huntington's chorea, glaucoma, nausea, anxiety, psychosis, attention deficit hyperactivity disorder, premature ejaculation, and stroke.Type: GrantFiled: February 25, 2009Date of Patent: March 2, 2010Assignee: Sepracor Inc.Inventors: Brian M. Aquila, Seth C. Hopkins, Curtis A. Lockshin, Fengjiang Wang
-
Publication number: 20090163593Abstract: One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to asthma, neuropathic pain, persistent pain, inflammatory pain, hyperactivity, hypertension, brain ischemia, Parkinson's disease, spasticity, Tourette's syndrome, schizophrenia, hemorrhagic shock, septic shock, cardiac shock, migrane, Horton's headache, multiple sclerosis, anorexia, AIDS wasting syndrome, organ rejection, autoimmune diseases, allergy, arthritis, Crohn's disease, malignant gliomas, neurodegenerative diseases, Huntington's chorea, glaucoma, nausea, anxiety, psychosis, attention deficit hyperactivity disorder, premature ejaculation, and stroke.Type: ApplicationFiled: February 25, 2009Publication date: June 25, 2009Inventors: Brian M. Aquila, Seth C. Hopkins, Curtis A. Lockshin, Fengjiang Wang
-
Patent number: 7511073Abstract: One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to asthma, neuropathic pain, persistent pain, inflammatory pain, hyperactivity, hypertension, brain ischemia, Parkinson's disease, spasticity, Tourette's syndrome, schizophrenia, hemorrhagic shock, septic shock, cardiac shock, migrane, Horton's headache, multiple sclerosis, anorexia, AIDS wasting syndrome, organ rejection, autoimmune diseases, allergy, arthritis, Crohn's disease, malignant gliomas, neurodegenerative diseases, Huntington's chorea, glaucoma, nausea, anxiety, psychosis, attention deficit hyperactivity disorder, premature ejaculation, and stroke.Type: GrantFiled: May 23, 2006Date of Patent: March 31, 2009Assignee: Sepracor, Inc.Inventors: Brian M. Aquila, Seth C. Hopkins, Curtis A. Lockshin, Fengjiang Wang
-
Patent number: 7262856Abstract: A microstructure-based chemical sensor that can be interrogated by a remote observer. The device acts as an electromagnetic wave filter in the optical region of the spectrum, filtering one or more wavelength bands where the band spectral notch location shifts in response to the accumulation of material on the surface of the microstructure sensor. The apparatus has a substrate having a surface relief structure containing dielectric bodies with one or more physical dimensions smaller than the wavelength of the filtered electromagnetic waves, such structures repeated in an array covering at least a portion of the surface of the substrate. A retro-reflecting structure allows interrogation of the sensor over a wide field of view. The device is particularly useful as a water monitoring device in hard to reach locations, and as a chemical warfare or explosives detector that can be read from a safe distance.Type: GrantFiled: May 25, 2005Date of Patent: August 28, 2007Inventors: Douglas S. Hobbs, Curtis A. Lockshin, James J. Cowan, Robert B. Nilsen
-
Publication number: 20070190603Abstract: Described herein is the self-assembly of amphiphilic peptides, i.e., peptides with alternating hydrophobic and hydrophilic residues, into macroscopic membranes. The membrane-forming peptides are greater than 12 amino acids in length, and preferably at least 16 amino acids, are complementary and are structurally compatible. Specifically, two peptides, (AEAEAKAK)2 (ARARADAD)2, were shown to self-assemble into macroscopic membranes. Conditions under which the peptides self-assemble into macroscopic membranes and methods for producing the membranes are also described. The macroscopic membranes have several interesting properties: they are stable in aqueous solution, serum, and ethanol, are highly resistant to heat, alkaline and acidic pH, chemical denaturants, and proteolytic digestion, and are non-cytotoxic.Type: ApplicationFiled: August 29, 2006Publication date: August 16, 2007Inventors: Todd Holmes, Shuguang Zhang, Alexander Rich, C. DiPersio, Curtis Lockshin
-
Publication number: 20070036680Abstract: A microstructure-based chemical sensor that can be interrogated by a remote observer. The device acts as an electromagnetic wave filter in the optical region of the spectrum, filtering one or more wavelength bands where the band spectral notch location shifts in response to the accumulation of material on the surface of the microstructure sensor. The apparatus has a substrate having a surface relief structure containing dielectric bodies with one or more physical dimensions smaller than the wavelength of the filtered electromagnetic waves, such structures repeated in an array covering at least a portion of the surface of the substrate. A retro-reflecting structure allows interrogation of the sensor over a wide field of view. The device is particularly useful as a water monitoring device in hard to reach locations, and as a chemical warfare or explosives detector that can be read from a safe distance.Type: ApplicationFiled: May 25, 2005Publication date: February 15, 2007Inventors: Douglas Hobbs, Curtis Lockshin, James Cowan, Robert Nilsen
-
Publication number: 20060281742Abstract: One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to asthma, neuropathic pain, persistent pain, inflammatory pain, hyperactivity, hypertension, brain ischemia, Parkinson's disease, spasticity, Tourette's syndrome, schizophrenia, hemorrhagic shock, septic shock, cardiac shock, migrane, Horton's headache, multiple sclerosis, anorexia, AIDS wasting syndrome, organ rejection, autoimmune diseases, allergy, arthritis, Crohn's disease, malignant gliomas, neurodegenerative diseases, Huntington's chorea, glaucoma, nausea, anxiety, psychosis, attention deficit hyperactivity disorder, premature ejaculation, and stroke.Type: ApplicationFiled: May 23, 2006Publication date: December 14, 2006Inventors: Brian Aquila, Seth Hopkins, Curtis Lockshin, Fengjiang Wang
-
Patent number: 7098028Abstract: Described herein is the self-assembly of amphiphilic peptides, i.e., peptides with alternating hydrophobic and hydrophilic residues, into macroscopic membranes. The membrane-forming peptides are greater than 12 amino acids in length, and preferably at least 16 amino acids, are complementary and are structurally compatible. Specifically, two peptides, (AEAEAKAK)2 (ARARADAD)2, were shown to self-assemble into macroscopic membranes. Conditions under which the peptides self-assemble into macroscopic membranes and methods for producing the membranes are also described. The macroscopic membranes have several interesting properties: they are stable in aqueous solution, serum, and ethanol, are highly resistant to heat, alkaline and acidic pH, chemical denaturants, and proteolytic digestion, and are non-cytotoxic.Type: GrantFiled: March 17, 2003Date of Patent: August 29, 2006Assignee: Massachusetts Institute of TechnologyInventors: Todd Holmes, Shuguang Zhang, Alexander Rich, C. Michael DiPersio, Curtis Lockshin
-
Patent number: 7049329Abstract: One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to asthma, neuropathic pain, persistent pain, inflammatory pain, hyperactivity, hypertension, brain ischemia, Parkinson's disease, spasticity, Tourette's syndrome, schizophrenia, hemorrhagic shock, septic shock, cardiac shock, migrane, Horton's headache, multiple sclerosis, anorexia, AIDS wasting syndrome, organ rejection, autoimmune diseases, allergy, arthritis, Crohn's disease, malignant gliomas, neurodegenerative diseases, Huntington's chorea, glaucoma, nausea, anxiety, psychosis, attention deficit hyperactivity disorder, premature ejaculation, and stroke.Type: GrantFiled: May 15, 2003Date of Patent: May 23, 2006Assignee: Sepracor Inc.Inventors: Brian M. Aquila, Seth C. Hopkins, Curtis A. Lockshin, Fengjiang Wang
-
Patent number: 6800481Abstract: Described herein is the self-assembly of amphiphilic peptides, i.e., peptides with alternating hydrophobic and hydrophilic residues, into macroscopic membranes. The membrane-forming peptides are greater than 12 amino acids in length, and preferably at least 16 amino acids, are complementary and are structurally compatible. Specifically, two peptides, (AEAEAKAK)2 (ARARADAD)2, were shown to self-assemble into macroscopic membranes. Conditions under which the peptides self-assemble into macroscopic membranes and methods for producing the membranes are also described. The macroscopic membranes have several interesting properties: they are stable in aqueous solution, serum, and ethanol, are highly resistant to heat, alkaline and acidic pH, chemical denaturants, and proteolytic digestion, and are non-cytotoxic.Type: GrantFiled: March 26, 1997Date of Patent: October 5, 2004Assignee: Massachusetts Institute of TechnologyInventors: Todd Holmes, Shuguang Zhang, Alexander Rich, C. Michael DiPersio, Curtis Lockshin
-
Publication number: 20040087013Abstract: Described herein is the self-assembly of amphiphilic peptides, i.e., peptides with alternating hydrophobic and hydrophilic residues, into macroscopic membranes. The membrane-forming peptides are greater than 12 amino acids in length, and preferably at least 16 amino acids, are complementary and are structurally compatible. Specifically, two peptides, (AEAEAKAK)2 (ARARADAD)2, were shown to self-assemble into macroscopic membranes. Conditions under which the peptides self-assemble into macroscopic membranes and methods for producing the membranes are also described. The macroscopic membranes have several interesting properties: they are stable in aqueous solution, serum, and ethanol, are highly resistant to heat, alkaline and acidic pH, chemical denaturants, and proteolytic digestion, and are non-cytotoxic.Type: ApplicationFiled: March 17, 2003Publication date: May 6, 2004Inventors: Todd Holmes, Shuguang Zhang, Alexander Rich, C. Michael DiPersio, Curtis Lockshin
-
Publication number: 20040048907Abstract: One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to asthma, neuropathic pain, persistent pain, inflammatory pain, hyperactivity, hypertension, brain ischemia, Parkinson's disease, spasticity, Tourette's syndrome, schizophrenia, hemorrhagic shock, septic shock, cardiac shock, migrane, Horton's headache, multiple sclerosis, anorexia, AIDS wasting syndrome, organ rejection, autoimmune diseases, allergy, arthritis, Crohn's disease, malignant gliomas, neurodegenerative diseases, Huntington's chorea, glaucoma, nausea, anxiety, psychosis, attention deficit hyperactivity disorder, premature ejaculation, and stroke.Type: ApplicationFiled: May 15, 2003Publication date: March 11, 2004Inventors: Brian M. Aquila, Seth C. Hopkins, Curtis A. Lockshin, Fengjiang Wang
-
Patent number: 6548630Abstract: Described herein is the self-assembly of amphiphilic peptides, i.e., peptides with alternating hydrophobic and hydrophilic residues, into macroscopic membranes. The membrane-forming peptides are greater than 12 amino acids in length, and preferably at least 16 amino acids, are complementary and are structurally compatible. Specifically, two peptides, (AEAEAKAK)2 (ARARADAD)2, were shown to self-assemble into macroscopic membranes. Conditions under which the peptides self-assemble into macroscopic membranes and methods for producing the membranes are also described. The macroscopic membranes have several interesting properties: they are stable in aqueous solution, serum, and ethanol, are highly resistant to heat, alkaline and acidic pH, chemical denaturants, and proteolytic digestion, and are non-cytotoxic.Type: GrantFiled: July 22, 1997Date of Patent: April 15, 2003Assignee: Massachusettes Insitute of TechnologyInventors: Shuguang Zhang, Curtis Lockshin, Alexander Rich, Todd Holmes
-
Patent number: 5955343Abstract: Described herein is the self-assembly of amphiphilic peptides, i.e., peptides with alternating hydrophobic and hydrophilic residues, into macroscopic membranes. The membrane-forming peptides are greater than 12 amino acids in length, and preferably at least 16 amino acids, are complementary and are structurally compatible. Specifically, two peptides, (AEAEAKAK).sub.2 (ARARADAD).sub.2, were shown to self-assemble into macroscopic membranes. Conditions under which the peptides self-assemble into macroscopic membranes and methods for producing the membranes are also described. The macroscopic membranes have several interesting properties: they are stable in aqueous solution, serum, and ethanol, are highly resistant to heat, alkaline and acidic pH, chemical denaturants, and proteolytic digestion, and are non-cytotoxic.Type: GrantFiled: August 22, 1994Date of Patent: September 21, 1999Assignee: Massachusetts Institute of TechnologyInventors: Todd Holmes, Shuguang Zhang, Alexander Rich, C. Michael DiPersio, Curtis Lockshin
-
Patent number: 5670483Abstract: Described herein is the self-assembly of amphiphilic peptides, i.e., peptides with alternating hydrophobic and hydrophilic residues, into macroscopic membranes. The membrane-forming peptides are greater than 12 amino acids in length, and preferably at least 16 amino acids, are complementary and are structurally compatible. Specifically, two peptides, (AEAEAKAK).sub.2 (ARARADAD).sub.2, were shown to self-assemble into macroscopic membranes. Conditions under which the peptides self-assemble into macroscopic membranes and methods for producing the membranes are also described. The macroscopic membranes have several interesting properties: they are stable in aqueous solution, serum, and ethanol, are highly resistant to heat, alkaline and acidic pH, chemical denaturants, and proteolytic digestion, and are non-cytotoxic.Type: GrantFiled: November 30, 1994Date of Patent: September 23, 1997Assignee: Massachusetts Insititute of TechnologyInventors: Shuguang Zhang, Curtis Lockshin, Alexander Rich, Todd Holmes